Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targeted radiotherapy (TRT), supporting the advancement of discovery and preclinical programs.
The collaboration builds on an existing relationship between the two organizations and focuses on securing the supply of radionuclides that remain difficult to access at scale. This is particularly relevant for astatine-211, an alpha-emitting radioisotope which is the subject of increasing scientific interest but has limited availability due to production and logistical constraints.
GIP ARRONAX, a French research institute specializing in the development and production of innovative radionuclides, already supplies lead-203 (Pb-203) and copper-64 (Cu-64) to Oncodesign Services. The extended collaboration now includes astatine-211, enabling continued access for programs requiring this isotope.
“Astatine-211 is attracting attention due to its favorable nuclear properties and potential application in targeted radiotherapy,” said Dr. Aidan Synnott, CEO, Oncodesign Services. “However, its short half-life and limited production capacity make access and logistics critical. Extending our collaboration with GIP ARRONAX helps address these constraints and supports continuity in preclinical programs.”
Astatine-211 has a half-life of approximately seven hours, meaning that production, transport and study execution must be tightly coordinated. Securing access to such radionuclides is a prerequisite for generating robust and interpretable preclinical data in TRT programs.
“We have been working with astatine-211 for many years, producing it on a very regular basis and supporting its transition to GMP production and clinical trials”, said Pr Ferid Haddad, GIP ARRONAX Director . “Our experience covers the full development chain from isotope production to radiolabeling scale-up and IMPD preparation and clinical dose delivery, partnering with several companies developing next-generation alpha-emitter therapies.”